A recent study reveals that individuals who discontinue popular GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who end traditional diet and exercise plans.
Findings released in a major health publication shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals buying such treatments need to be cognizant of the potential of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.
Such speed of regain means a return to starting weight in about a year and a half.
Analyzing Treatments
The research, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists note that people who shed pounds through lifestyle changes alone typically experience a less rapid weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts propose the mode of action of the drugs accounts for the amplified regain.
The injections imitate a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals say that, considering the high risk of relapse, the therapy might need to be ongoing.
This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have stopped the medication describe a sudden return of hunger.
"I experienced a switch flipping and you become ravenous," recalled one woman.
This challenge is compounded if individuals have not established sustainable lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic solution and long-term success relies on integrated lifestyle support.
